Global Travel Sickness Drugs Market Size By Type (Anticholinergic, Antihistamines), By Application (Adults, Children), By Region, And Segment Forecasts, 2023 to 2032

The Global Travel Sickness Drugs Market was valued at USD 610 million in 2023 and is projected to surpass USD 945 million by 2031, growing at a CAGR of 5.6% during the forecast period from 2023 to 2031. This growth is fueled by the increasing incidence of motion sickness among travelers, the rising popularity of travel and tourism, and the broadening availability of over-the-counter (OTC) and prescription medications that alleviate symptoms such as nausea, dizziness, and vomiting.

As awareness around travel-induced health discomfort rises, pharmaceutical companies are investing in innovative formulations and delivery systems—such as patches, gummies, and non-drowsy pills—to expand their reach to different age groups and demographic segments.

Drivers:

1. Growth in Global Travel & Tourism:

The increase in international and domestic travel post-pandemic has led to a corresponding rise in motion sickness cases, particularly among air, sea, and road travelers, fueling demand for effective treatment options.

2. Expanding Geriatric and Pediatric Population:

Older adults and children are particularly susceptible to travel sickness. Rising global geriatric and pediatric populations contribute to higher consumption of travel sickness drugs.

3. Availability of Diverse Drug Forms:

The wide availability of travel sickness drugs in various forms (chewable tablets, oral liquids, transdermal patches, etc.) has enhanced patient compliance and broadened the consumer base.

Restraints:

1. Side Effects of Medications:

Some travel sickness drugs are associated with side effects such as drowsiness, dry mouth, and blurred vision, which may deter usage, especially among active travelers and drivers.

2. Growing Preference for Natural Remedies:

Increasing consumer inclination toward herbal and non-pharmacological remedies may limit the market potential for synthetic drugs, especially in wellness-focused demographics.

Opportunity:

1. E-commerce and Digital Health Channels:

The rise of online pharmacies and health platforms has enabled easier access to travel sickness medications, especially in remote or underserved areas.

2. Product Innovation and Pediatric Formulations:

There is a significant opportunity in developing drug variants specifically tailored to pediatric needs (milder dosages, better taste, and ease of administration), as well as non-drowsy alternatives for active travelers.

Market by System Type Insights:

Based on system type, antihistamines dominated the market in 2023. These drugs, including meclizine and dimenhydrinate, are widely preferred due to their rapid action and effectiveness in controlling motion-induced nausea and dizziness. Meanwhile, the anticholinergics segment, primarily consisting of scopolamine patches, is expected to register the fastest growth due to their longer duration of action and popularity among cruise travelers.

Market by End-use Insights:

In terms of end-use, over-the-counter (OTC) medications held the largest share in 2023, accounting for more than 60% of the market. Increasing consumer confidence in self-medication and easy accessibility of non-prescription drugs have driven this segment’s growth. However, the prescription drugs segment is anticipated to witness steady growth among patients with chronic vestibular disorders or under physician-recommended travel medication plans.

Market by Regional Insights:

North America led the global market in 2023, driven by high awareness, strong healthcare infrastructure, and the high prevalence of motion sickness among frequent travelers. Asia-Pacific, however, is forecast to be the fastest-growing region through 2031 due to expanding tourism, urbanization, and increased spending on health and wellness products in countries like China, India, and Southeast Asia.

Competitive Scenario:

Key players operating in the Global Travel Sickness Drugs Market include:

GlaxoSmithKline plc (maker of Dramamine)

Prestige Consumer Healthcare Inc.

Baxter International Inc.

Perrigo Company plc

WellSpring Consumer Healthcare

Myungmoon Pharmaceutical Co., Ltd.

Bayer AG

Johnson & Johnson

These companies focus on expanding their product portfolios, strategic acquisitions, and enhancing online sales channels. For instance:

In 2023, GlaxoSmithKline launched a new non-drowsy travel sickness chewable tailored for children aged 6–12.

In 2024, Prestige Consumer Healthcare expanded its digital outreach through e-pharmacy partnerships across North America and Europe.

In 2025, Bayer AG introduced a herbal-based motion sickness tablet with ginger extracts targeted at wellness-conscious travelers.

Scope of Work – Global Travel Sickness Drugs Market

Key Market Developments:

July 2023: Prestige Consumer Healthcare introduced travel-friendly packaging for its motion sickness chewables to enhance portability for tourists.

February 2024: Johnson & Johnson began clinical trials for a long-acting, non-sedative oral motion sickness medication aimed at frequent flyers.

April 2025: Perrigo Company partnered with regional retailers in Southeast Asia to launch localized travel sickness products.

FAQs:

1. What is the current market size of the Global Travel Sickness Drugs Market?

The Global Travel Sickness Drugs Market was valued at USD 610 million in 2023.

2. What is the major growth driver of the Global Travel Sickness Drugs Market?

The major growth driver is the surge in global travel and tourism, increasing cases of motion sickness, and growing awareness about symptom management.

3. Which is the largest region during the forecast period in the Global Travel Sickness Drugs Market?

North America is the largest region, while Asia-Pacific is expected to grow at the fastest rate.

4. Which segment accounted for the largest market share in the Global Travel Sickness Drugs Market?

The over-the-counter (OTC) segment accounted for the largest market share in 2023.

5. Who are the key market players in the Global Travel Sickness Drugs Market?

Key players include GlaxoSmithKline plc, Prestige Consumer Healthcare Inc., Baxter International Inc., Bayer AG, and Johnson & Johnson.